/
RDHL
$0.86-$0.02 (-2.11%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$4.6M
5M shares
52-week range
$0.71 – $3.31
6% from low
Exchange
NASDAQ
ADRC
Borrow rate
35.30%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-6879.14
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $8.4M | $6.3M | $64.4M | $85.8M | $61.8M | $6.5M | $8.0M | $286.0K |
| Cost of revenue | $2.8M | $2.3M | $36.9M | $49.4M | $33.3M | $3.5M | $3.2M | $0 |
| Gross profit | $5.5M | $4.0M | $27.5M | $36.4M | $28.5M | $3.1M | $4.9M | $286.0K |
| Gross margin | 66.1% | 64.1% | 42.7% | 42.4% | 46.1% | 47.0% | 60.3% | 100.0% |
| R&D | $24.9M | $17.4M | $16.5M | $29.5M | $7.3M | $3.5M | $1.6M | $2.0M |
| Operating income | −$39.3M | −$43.2M | −$63.7M | −$81.1M | −$42.8M | $12.6M | −$14.6M | −$7.9M |
| EBITDA | −$38.7M | −$40.7M | −$55.0M | −$63.0M | −$22.2M | $26.3M | −$7.6M | −$7.7M |
| Net income | −$38.8M | −$42.3M | −$76.2M | −$97.7M | −$71.7M | $23.9M | −$8.3M | −$429.0K |
| Net margin | -464.4% | -672.5% | -118.4% | -114.0% | -116.0% | 366.2% | -102.8% | -150.0% |
| EPS (diluted) | -850.00 | -700.00 | -1000.00 | -1000.00 | -600.00 | 46.00 | -7.00 | 0.00 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $51M | $0.00 | $0.00–$0.00 | 0 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Redhill Biopharma Ltd.
RedHill Biopharma Ltd is a specialty biopharmaceutical company mainly focused on the U.S. development and commercialization of drugs for GI diseases, infectious diseases, and oncology. The Company is mainly focused on the advancement of its development pipeline of clinical-stage therapeutic candidates and also commercializes its GI-related product, Talicia (omeprazole, amoxicillin, and rifabutin) in the U.S. Its therapeutic candidates include opaganib, RHB-204, RHB-104, RHB-102 (Bekinda), and RHB-107.
www.redhillbio.com- Employees
- 23
- IPO / List date
- Jan 7, 2013
Held by traders on TradeandTell
No one on the platform currently holds RDHL.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in RDHL as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2024-08-20 | 1-for-25reverse |
| 2023-03-23 | 1-for-40reverse |
Recent trades on TradeandTell
No one on the platform has traded RDHL yet.
